Literature DB >> 7561689

Autoantibodies from patients with primary biliary cirrhosis preferentially react with the amino-terminal domain of nuclear pore complex glycoprotein gp210.

J Wesierska-Gadek1, H Hohenauer, E Hitchman, E Penner.   

Abstract

Patients with primary biliary cirrhosis frequently develop autoantibodies directed to gp210, a major glycoprotein of the nuclear pore complex. This protein contains a large glycosylated cisternal domain, a single transmembrane segment, and a short cytoplasmic tail. It has been previously shown that autoantibodies from primary biliary cirrhosis patients exclusively react with the cytoplasmic tail. We demonstrate that autoantibodies against gp210 recognize at least two different epitopes. 4 out of 12 anti-gp210 positive sera reacted with the fragment consisting of the cytoplasmic tail, and 8 sera targeted a novel epitope located within the large glycosylated lumenal domain. Moreover, our data prove that carbohydrate moieties are an essential part of this novel epitope. We propose, therefore, that future screening assays should be performed with antigens possessing both epitopes to detect all sera with anti-gp210 specificity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561689      PMCID: PMC2192276          DOI: 10.1084/jem.182.4.1159

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  9 in total

Review 1.  Autoantibodies against nuclear envelope proteins in liver disease.

Authors:  H J Worman; J C Courvalin
Journal:  Hepatology       Date:  1991-12       Impact factor: 17.425

2.  Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis.

Authors:  K Lassoued; R Brenard; F Degos; J C Courvalin; C Andre; F Danon; J C Brouet; Y Zine-el-Abidine; C Degott; S Zafrani
Journal:  Gastroenterology       Date:  1990-07       Impact factor: 22.682

3.  The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore.

Authors:  J C Courvalin; K Lassoued; E Bartnik; G Blobel; R W Wozniak
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  A major glycoprotein of the nuclear pore complex is a membrane-spanning polypeptide with a large lumenal domain and a small cytoplasmic tail.

Authors:  U F Greber; A Senior; L Gerace
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

6.  Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease.

Authors:  J Wesierska-Gadek; E Penner; E Hitchman; P Kier; G Sauermann
Journal:  Blood       Date:  1992-02-15       Impact factor: 22.113

7.  Primary structure analysis of an integral membrane glycoprotein of the nuclear pore.

Authors:  R W Wozniak; E Bartnik; G Blobel
Journal:  J Cell Biol       Date:  1989-06       Impact factor: 10.539

8.  A modified procedure for the isolation of a pore complex-lamina fraction from rat liver nuclei.

Authors:  N Dwyer; G Blobel
Journal:  J Cell Biol       Date:  1976-09       Impact factor: 10.539

9.  Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210.

Authors:  R E Nickowitz; H J Worman
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

  9 in total
  14 in total

1.  Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis.

Authors:  L M Stinton; M Swain; R P Myers; A A Shaheen; M J Fritzler
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

2.  Differential detection of nuclear envelope autoantibodies in primary biliary cirrhosis using routine and alternative methods.

Authors:  Elena Tsangaridou; Hara Polioudaki; Rania Sfakianaki; Martina Samiotaki; Maria Tzardi; Meri Koulentaki; George Panayotou; Elias Kouroumalis; Elias Castanas; Panayiotis A Theodoropoulos
Journal:  BMC Gastroenterol       Date:  2010-03-08       Impact factor: 3.067

3.  Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries.

Authors:  E Jensen-Jarolim; C Neumann; G Oberhuber; R Gscheidlinger; C Neuchrist; W Reinisch; R I Zuberi; E Penner; F T Liu; G Boltz-Nitulescu
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

Review 4.  Primary biliary cirrhosis and the nuclear pore complex.

Authors:  Carolina Duarte-Rey; Dimitrios Bogdanos; Chen-Yen Yang; Krista Roberts; Patrick S C Leung; Juan-Manuel Anaya; Howard J Worman; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2012-04-01       Impact factor: 9.754

Review 5.  Autoantigens in primary biliary cirrhosis.

Authors:  D E Jones
Journal:  J Clin Pathol       Date:  2000-11       Impact factor: 3.411

Review 6.  Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases.

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 7.  Autoantigens of the nuclear pore complex.

Authors:  P Enarson; J B Rattner; Y Ou; K Miyachi; T Horigome; M J Fritzler
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

8.  Diagnostic value of anti-gp210 antibodies in primary biliary cirrhosis: a case-based review.

Authors:  Florent Valour; Stéphane Durupt; Safia Khenifer; Isabelle Durieu
Journal:  BMJ Case Rep       Date:  2013-06-26

9.  Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis.

Authors:  Alicja Bauer; Andrzej Habior
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

10.  Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What's New?

Authors:  Daniel S Smyk; Eirini I Rigopoulou; Dimitrios P Bogdanos
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.